Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility

Gene

Volumn 497, Issue 2, 2012, Pages 273-279

  Divyya, Shree ^a   Naushad, Shaik Mohammad ^a   Addlagatta, Anthony ^b   Murthy, P V L N ^a   Reddy, Ch Ram ^a   Digumarti, Raghunadha Rao ^a   Gottumukkala, Suryanarayana Raju ^a   Kumar, Ajit ^a   Rammurti, S ^a   Kutala, Vijay Kumar ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Autism; Cancer; Coronary artery disease; Glutamate carboxypeptidase II; Polymorphism

Indexed keywords

FOLIC ACID; GLUTAMATE CARBOXYPEPTIDASE II;

ARTICLE; AUTISM; BREAST CANCER; CATALYSIS; COMPUTER MODEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIETARY INTAKE; DISEASE PREDISPOSITION; FOLIC ACID BLOOD LEVEL; GENE EXPRESSION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTESTINE ABSORPTION; LIGAND BINDING; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ANTIGENS, SURFACE; AUTISTIC DISORDER; BREAST NEOPLASMS; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 84862786624     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.01.055     Document Type: Article

References (55)

1. Afman L.A., Trijbels F.J., Blom H.J. The H475Y polymorphism in the glutamate carboxypeptidase II gene increases plasma folate without affecting the risk for neural tube defects in humans. J. Nutr. 2003, 133(1):75-77.
2. Altschul S.F., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25(17):3389-3402.
3. Bacich D.J., et al. Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J. Neurochem. 2005, 95(2):314-323.
4. Blundell G., Jones B.G., Rose F.A., Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996, 122(2):163-172.
5. Buxbaum J.D., et al. Association between a GABRB3 polymorphism and autism. Mol. Psychiatry 2002, 7:311-316.
6. Carlsson M.L. Hypothesis: is infantile autism a hypoglutmatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy. J. Neural Transm. 1998, 105:525-535.
7. Carrell D.T., et al. Elevated sperm chromosome aneuploidy and apoptosis in patients with unexplained recurrent pregnancy loss. Obstet. Gynecol. 2003, 101(6):1229-1235.
8. Carter R.E., Berger U.V., Barczak A.K., Enna M., Coyle J.T. Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3215-3220.
9. Chandler C.J., Wang T.T., Halsted C.H. Pteroylpolyglutamate hydrolase from human jejunal brush borders. Purification and characterization. J. Biol. Chem. 1986, 261(2):928-933.
10. Chang Sam S., Reuter Victor E., Heston W.D.W., Bander Neil H., Grauer Lana S., Gaudin Paul B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999, 59:3192-3198.
11. Choi D.W. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci. Lett. 1985, 58:293-297.
12. Collin S.M., et al. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2009, 18(9):2528-2539.
13. Devlin A.M., et al. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum. Mol. Genet. 2000, 9(19):2837-2844.
14. D'Uva M., et al. Hyperhomocysteinemia in women with unexplained sterility or recurrent early pregnancy loss from Southern Italy: a preliminary report. Thromb. J. 2007, 11:5-10.
15. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60(Pt 12 Pt 1):2126-2132.
16. Ghadge G.D., et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl. Acad. Sci. 2003, 100:9554-9559.
17. Govindaiah V., Naushad S.M., Prabhakara K., Krishna P.C., Radha Rama Devi A. Association of parental hyperhomocysteinemia and C677T Methylene tetrahydrofolate reductase (MTHFR) polymorphism with recurrent pregnancy loss. Clin. Biochem. 2009, 42(4-5):380-386.
18. Halsted C.H., Ling E.H., Luthi-Carter R., Villanueva J.A., Gardner J.M., Coyle J.T. Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum: molecular characterization and relation to glutamate carboxypeptidase II. J. Biol. Chem. 1998, 273(32):20417-20424.
19. Halsted Charles H., et al. Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study. Am. J. Clin. Nutr. 2007, 86:514-521.
20. Hussman J.P. Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. J. Autism Dev. Disord. 2001, 31:247-248.
21. Israeli R.S., Powell C.T., Fair W.R., Heston W.D.W. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993, 53:227-230.
22. Jiang Y., et al. Homocysteine-induced extracellular superoxide dismutase and its epigenetic mechanisms in monocytes. J. Exp. Biol. 2008, 211(Pt 6):911-920.
23. Kumar K.S., Govindaiah V., Naushad S.E., Devi R.R., Jyothy A. Plasma homocysteine levels correlated to interactions between folate status and methylene tetrahydrofolate reductase gene mutation in women with unexplained recurrent pregnancy loss. J. Obstet. Gynaecol. 2003, 23(1):55-88.
24. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. NEJM 1994, 330:613-622.
25. Lumley L.A., Robison C.L., Slusher B.S., Wozniak K., Dawood M., Meyerhoff J.L. Reduced isolation-induced aggressiveness in mice following NAALADase inhibition. Psychopharmacology (Berl) 2004, 171(4):375-381.
26. Luthi-Carter R., Barczak A.K., Speno H., Coyle J.T. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J. Pharmacol. Exp. Ther. 1998, 286(2):1020-1025. Aug.
27. Maraj B.H., Leek J.P., Karayi M., Ali M., Lench N.J., Markham A.F. Detailed genetic mapping around a putative prostate-specific membrane antigen locus on human chromosome 11p11.2. Cytogenet. Cell Genet. 1998, 81:3-9.
28. Mesters J.R., et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006, 25(6):1375-1384.
29. Morin I., et al. Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk. Mol. Genet. Metab. 2003, 79(3):197-200.
30. Naushad S.M., Devi A.R. Role of parental folate pathway single nucleotide polymorphisms in altering the susceptibility to neural tube defects in South India. J. Perinat. Med. 2010, 38(1):63-69.
31. Naushad S.M., Pavani A., Digumarti R.R., Gottumukkala S.R., Kutala V.K. Epistatic interactions between loci of one-carbon metabolism modulate susceptibility to breast cancer. Mol. Biol. Rep. 2011, 38(8):4893-4901.
32. Naushad S.M., et al. Cross-talk between one-carbon metabolism and xenobiotic metabolism: implications on oxidative DNA damage and susceptibility to breast cancer. Cell Biochem. Biophys. 2011, 61(3):715-723.
33. Nelen W.L., Blom H.J., Steegers E.A., den Heijer M., Thomas C.M., Eskes T.K. Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. Obstet. Gynecol. 2000, 95(4):519-524.
34. Nilsson M., Waters S., Waters N., Carlsson A., Carlsson M.L. A behavioural pattern analysis of hypoglutamatergic mice-effects of four different antipsychotic agents. J. Neural Transm. 2001, 108:1181-1196.
35. Nishio E., Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br. J. Pharmacol. 1997, 122(2):269-274.
36. O'Keefe D.S., et al. Mapping, genomic organization and promoter analysis of the human prostatespecific membrane antigen gene. Biochim. Biophys. Acta 1998, 1443:113-127.
37. Parathath S.R., Parathath S., Tsirka S.E. Nitric oxide mediates neurodegeneration and breakdown blood-brain barrier in tPA dependent excitotoxic injury in mice. J. Cell Sci. 2006, 119:339-349.
38. Rajasekaran A.K., Anilkumar G., Christiansen J.J. Is prostate-specific membrane antigen a multifunctional protein?. Am. J. Physiol. Cell Physiol. 2005, 288(5):C975-C981.
39. Relton C.L., Wilding C.S., Jonas P.A., Lynch S.A., Tawn E.J., Burn J. Genetic susceptibility to neural tube defect pregnancy varies with offspring phenotype. Clin. Genet. 2003, 64(5):424-428.
40. Sanabria E.R., Wozniak K.M., Slusher B.S., Keller A. GCPII (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J. Neurophysiol. 2004, 91(1):182-193.
41. Smithells R.W., Sheppard S., Schorah C.J. Vitamin deficiencies and neural tube defects. Arch. Dis. Child. 1976, 51:944-950.
42. Steegers-Theunissen R.P., Steegers E.A., de Boer R., Thomas C.M., Kloosterman M.D., Eskes T.K. Elevated folate levels in amniotic fluid after oral supplementation. Eur. J. Obstet. Gynecol. Reprod. Biol. 1990, 36(3):283-291.
43. Steegers-Theunissen R.P., et al. Maternal hyperhomocysteinemia: a risk factor for neural tube defects?. Metabolism 1994, 43:1475-1480.
44. Thomas A.G., et al. Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta. Eur. J. Pharmacol. 2001, 430(1):33-40.
45. Trková M., Kapras J., Bobková K., Stanková J., Mejsnarová B. Increased micronuclei frequencies in couples with reproductive failure. Reprod. Toxicol. 2000, 14(4):331-335.
46. Tyagi N., Sedoris K.C., Steed M., Ovechkin A.V., Moshal K.S., Tyagi S.C. Mechanisms of homocysteine-induced oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 2005, 289(6):H2649-H2656.
47. van den Berg H., van der Gaag M., Hendriks H. Influence of lifestyle on vitamin bioavailability. Int. J. Vitam. Nutr. Res. 2002, 72(1):53-59.
48. Vijaya Lakshmi S.V., Naushad S.M., Seshagiri Rao D., Kutala V.K. Oxidative stress is associated with genetic polymorphisms in one-carbon metabolism in coronary artery disease. Cell Biochem. Biophys. 2011, Dec 7. PMID:22147344.
49. Vinukonda G., Shaik Mohammad N., Md Nurul Jain J., Prasad Chintakindi K., Rama Devi Akella R. Genetic and environmental influences on total plasma homocysteine and coronary artery disease (CAD) risk among South Indians. Clin. Chim. Acta 2009, 405(1-2):127-131.
50. Vornov J.J., et al. Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG. Ann. N. Y. Acad. Sci. 1999, 890:400-516.
51. Voutilainen S., et al. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler. Thromb. Vasc. Biol. 1999, 19(5):1263-1266.
52. Warren, L.D., The PyMOL Molecular Graphics System, DeLano Scientific LLC, San Carlos, CA, USA. http://www.pymol.org.
53. Wright G.L., Haley C., Beckett M.L., Schellhammer P.F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1995, 1(1):18-28.
54. Xi Z.X., Baker D.A., Shen H., Carson D.S., Kalivas P.W. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accubens. J. Pharmacol. Exp. Ther. 2002, 300(1):162-171.
55. Yao V., Berkman C.E., Choi J.K., O'Keefe D.S., Bacich D.J. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 2010, 70(3):305-316.